Mucosal healing with methotrexate in Crohns disease: A prospective comparative study with azathioprine and infliximab

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 6, 2011, Pages 714-721

  Laharie, D ^a,b,c   Reffet, A ^a   Belleannee G ^a   Chabrun, E ^a   Subtil, C ^a   Razaire, S ^a   Capdepont, M ^a   De Ledinghen V ^a  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; METHOTREXATE;

ADULT; AGED; ARTICLE; COLONOSCOPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; ULCER HEALING;

EID: 79951674459     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04569.x     Document Type: Article

References (32)

1. Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohns disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8. (Pubitemid 350181602)
2. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohns disease. Evolution on prednisolone. Groupe dEtude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-8. (Pubitemid 20095830)
3. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohns disease. Gastrointest Endosc 2006; 63: 433-42. (Pubitemid 43261469)
4. Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133: 412-22. (Pubitemid 47187355)
5. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohns disease. Inflamm Bowel Dis 2009; 15: 1295-301.
6. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohns disease. Gastroenterology 2010; 138: 463-8.
7. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohns disease patients in stable remission on combined therapy with immunosuppressors: interim analysis of a prospective cohort study. Gut 2008; 57: A66.
8. Allez M, Lemann M, Bonnet J, et al. Long term outcome of patients with active Crohns disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol 2002; 97: 947-53. (Pubitemid 34408253)
9. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohns disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53. (Pubitemid 351783447)
10. Hebuterne X, Colombel JF, Bouhnik Y, et al. Endoscopic improvement in patients with active Crohns disease treated with certolizumab pegol: first results of the MUSIC clinical trial. Gut 2008; 57 (Suppl. 2): A-15.
11. Rutgeerts P,. Adalimumab induces and maintains mucosal healing in patients with moderate to severe ileocolonic Crohns disease. First results of the EXTEND trial. Gastroenterology 2009; 136 (Suppl. 1): A-116.
12. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohns disease. N Engl J Med 2010; 362: 1383-95.
13. Sandborn WJ, Van OE, Zins BJ, et al. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohns disease. Gastroenterology 1995; 109: 1808-17.
14. DHaens G, Geboes K, Ponette E, et al. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohns disease. Gastroenterology 1997; 112: 1475-81. (Pubitemid 27181370)
15. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6. (Pubitemid 19073651)
16. Manosa M, Naves JE, Leal C, et al. Does methotrexate induce mucosal healing in Crohns disease? Inflamm Bowel Dis 2010; 16: 377-8.
17. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53. (Pubitemid 43764536)
18. DHaens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohns disease: a European multicenter trial. Gastroenterology 1999; 116: 1029-34. (Pubitemid 29203012)
19. Mary JY, Modigliani R,. Development and validation of an endoscopic index of the severity for Crohns disease: a prospective multicentre study. Groupe dEtudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989; 30: 983-9.
20. Daperno M, DHaens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohns disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12. (Pubitemid 39311530)
21. Rutgeerts P, Vermeire S, Van Assche G,. Biological therapies for inflammatory bowel diseases. Gastroenterology 2009; 136: 1182-97.
22. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010; 7: 15-29.
23. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohns disease. The North American Crohns Study Group Investigators. N Engl J Med 1995; 332: 292-7.
24. Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohns disease. North American Crohns Study Group Investigators. N Engl J Med 2000; 342: 1627-32. (Pubitemid 30341531)
25. Lemann M, Mary JY, Colombel JF, et al. A randomized, double-blind, controlled withdrawal trial in Crohns disease patients in long-term remission on azathioprine. Gastroenterology 2005; 128: 1812-8. (Pubitemid 40824692)
26. Patel V, Macdonald JK, McDonald JW, Chande N,. Methotrexate for maintenance of remission in Crohns disease. Cochrane Database Syst Rev 2009; 4: CD006884.
27. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of Crohns disease: current management. J Crohn Colitis 2010; 4: 28-62.
28. Hausmann J, Zabel K, Herrmann E, et al. Methotrexate for maintenance of remission in chronic active Crohns disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010; 16: 1195-202.
29. Ng SC, Chan FK, Sung JJ,. Review article: the role of non-biological drugs in refractory inflammatory bowel disease. Aliment Pharmacol Ther 2011; 33: 417-27.
30. Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohns disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95: 1730-4. (Pubitemid 30485010)
31. Roumeguere P, Bouchard D, Pigot F, et al. Combined approach with infliximab, surgery, and methotrexate in severe fistulizing anoperineal Crohns disease: results from a prospective study. Inflamm Bowel Dis 2011; 17: 69-76.
32. Geboes K, Dalle I,. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50 (Suppl. 3): III37-42. (Pubitemid 34407455)